biotech
AbbVie/Roche gain FDA approval for blockbuster treatment
June 11, 2018Sales and Marketing AbbVie, Roche, biotech, drugs, pharma, pharmaceutical
AbbVie and Roche have a chalked up a major success, after the FDA gave its approval for Venclexta, in combination …
Takeda shareholders try to buck Shire deal
June 11, 2018Sales and Marketing Shire, Takeda, biotech, drugs, pharma, pharmaceutical
A small group of Takeda shareholders have started making a lot of noise over its $62 billion deal for Shire, …
EU gives nod to expanded label for AZ’s Tagrisso
June 11, 2018Sales and Marketing AstraZeneca, Tagrisso, biotech, drugs, pharma, pharmaceutical
AstraZeneca has scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line …
Ipsen set to relocate North American HQ to Boston
June 11, 2018Medical Communications, Sales and Marketing biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen is set to join the ranks of a number of Boston-based biotechs, by setting up shop in Kendall Square. …
Rubius Therapeutics brings in new CEO
June 11, 2018Medical Communications, Sales and Marketing Rubius Therapeutics, biotech, drugs, pharma, pharmaceutical
Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed …
Top Ten most popular articles on Pharmafile.com this week
June 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical
With ASCO occurring over the weekend, the headlines this week have been dominated by the news of breaking research that …
6.5% pay rise agreed for NHS staff
June 8, 2018Medical Communications NHS, biotech, drugs, pharma, pharmaceutical
After years of receiving only a 1% annual pay rise, NHS staff have voted to accept a 6.5% pay offer increase …
Pfizer successfully appeals 2,600% price hiking case
June 8, 2018Medical Communications Flynn Pharma, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer and co-defendant Flynn Pharma have won their appeal against a £90 million fine imposed on them by the Competition …
Bill Gates backed biotech reveals strategy
June 8, 2018Medical Communications Bill and Melinda Gates Foundation, biotech, drugs, pharma, pharmaceutical
The Bill and Melina Gates Foundation already funnels a large amount of money into aiding public health, particularly by funding …
Cancer Research UK unveil new Chief Business Officer
June 8, 2018Medical Communications Cancer Research UK, biotech, drugs, pharma, pharmaceutical
Cancer Research UK has appointed Tony Hickson to the position of Chief Business Officer. He arrives to the business from …
Parkinson’s disease: A quest for steadier therapies
June 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, biotech, drugs, pharma, pharmaceutical
The worrying number of deaths associated with Nuplazid has eyes returning to the pipeline for Parkinson’s disease. Anjali Shukla, a …
J&J looks to trim business with $2.8bn sale
June 7, 2018Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive …
Pfizer pumps $600m into venture fund, targeting neuroscience
June 7, 2018Research and Development, Sales and Marketing Pfizer, biotech, drugs, neuroscience, pharma, pharmaceutical
Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an …
Forty Seven springs out of the blocks ahead of IPO
June 7, 2018Research and Development, Sales and Marketing Forty Seven, biotech, drugs, pharma, pharmaceutical
Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …
Axovant attempts to rise from ashes with $842m Parkinson’s therapy deal
June 7, 2018Sales and Marketing Axovant, Oxford BioMedica, biotech, drugs, pharma, pharmaceutical
Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, …
Latest content
